Welcome to our dedicated page for Dexcom SEC filings (Ticker: DXCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dexcom’s CGM sensors may be tiny, but the disclosures behind them are anything but. Each annual report details sensor accuracy studies, reimbursement progress, and manufacturing scale that drive the company’s growth. If you have ever searched for the G7 margin breakout or the cost of disposable sensors, you know the data is buried deep inside SEC exhibits.
Stock Titan’s AI engine makes those details surface quickly. Our platform delivers Dexcom SEC filings explained simply and tags the passages investors care about—whether it is an 8-K announcing an FDA clearance or the footnote that spells out international revenue. Get instant alerts for Dexcom Form 4 insider transactions real-time and track every share purchase or sale by executives. For deeper diligence, compare the Dexcom quarterly earnings report 10-Q filing against the prior period with side-by-side AI summaries.
Here is what you can explore in one place:
- Dexcom annual report 10-K simplified – sensor unit economics, R&D spending, and risk factors distilled into plain English.
- Dexcom 8-K material events explained – from product recalls to strategic partnerships.
- Dexcom executive stock transactions Form 4 – pattern recognition on option exercises and sales.
- Dexcom proxy statement executive compensation – understand incentive structures tied to new product launches.
Whether you need a quick Dexcom earnings report filing analysis before the call or are understanding Dexcom SEC documents with AI for a full valuation model, Stock Titan provides comprehensive coverage and real-time updates. No more hunting through EDGAR—critical insights on Dexcom insider trading Form 4 transactions land in your dashboard the moment they post.
DexCom (NASDAQ: DXCM) Officer Sadie Stern has filed a Form 144 notice indicating a proposed sale of 1,466 shares of common stock with an aggregate market value of $124,697.96. The planned transaction is scheduled for execution on June 26, 2025, through Morgan Stanley Smith Barney LLC.
The shares to be sold were acquired as Restricted Stock from the issuer on November 19, 2023. The filing also discloses Stern's recent trading activity, showing three previous sales in May 2025 totaling 6,184 shares with combined gross proceeds of $526,318.38.
The transaction is being executed under a Rule 10b5-1 trading plan adopted on February 20, 2025. As of the filing date, DexCom has 392,107,501 shares outstanding. The seller has certified no knowledge of material adverse non-public information regarding the company's operations.
DexCom Director Mark G. Foletta reported significant insider trading activity through a pre-planned 10b5-1 sale. On June 16, 2025, Foletta's Family Trust sold 2,750 shares at a weighted average price of $83.129 per share, executed through multiple trades ranging from $82.635 to $83.61.
Following the transaction, Foletta maintains beneficial ownership of:
- 56,621 shares held indirectly through The Foletta Family Trust DTD 1/30/2015
- 5,731 unvested restricted stock units granted on May 8, 2025, which will vest on the earlier of the one-year anniversary or DexCom's 2026 Annual Meeting
The sale was executed under a 10b5-1 trading plan adopted by the Trust on March 13, 2025, designed to enable orderly disposition of shares. This transaction demonstrates planned insider selling activity while maintaining substantial equity position in the company.
FAQ
What is the current stock price of Dexcom (DXCM)?
What is the market cap of Dexcom (DXCM)?
What is the primary focus of Dexcom Inc?
How does Dexcom Inc integrate its technology with insulin delivery systems?
Who are the primary customers of Dexcom Inc?
What differentiates Dexcom Inc from other diabetes care companies?
How does Dexcom Inc generate revenue?
What is the competitive landscape for Dexcom Inc in the medical device industry?
